Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

69.63 +0.15 (+0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axonics Inc

< Previous 1 2 3 Next >
Axonics to Participate in the SUFU 2023 Winter Meeting
From Axonics, Inc.
Via Business Wire
Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics to Report Fourth Quarter 2022 Financial Results on March 1
From Axonics, Inc.
Via Business Wire
Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
From Axonics, Inc.
Via Business Wire
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in the Piper Sandler Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
From Axonics, Inc.
Via Business Wire
Axonics® Reports Third Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Is This Medical Gear Maker Ready To Continue Its Rally?
Medical gear maker Axonics rallied to a new high after an announcement that it entered the Canadian market. Is it set for bigger gains on strong revenue growth? 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in September Investor Conferences
From Axonics, Inc.
Via Business Wire
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
From Axonics, Inc.
Via Business Wire
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock
From Axonics, Inc.
Via Business Wire
Axonics® Announces Pricing of Public Offering of Common Stock
From Axonics, Inc.
Via Business Wire
Axonics® Announces Proposed Public Offering of Common Stock
From Axonics, Inc.
Via Business Wire
Axonics® Reports Second Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® to Report Second Quarter 2022 Financial Results on August 1
From Axonics, Inc.
Via Business Wire
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator
From Axonics, Inc.
Via Business Wire
Axonics® Reports First Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics® to Report First Quarter 2022 Financial Results on May 5
From Axonics, Inc.
Via Business Wire
Axonics® Launches Direct to Consumer Television Advertising Campaign
From Axonics, Inc.
Via Business Wire
Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in SVB Leerink Virtual Healthcare Conference
From Axonics, Inc.
Via Business Wire
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
From Axonics, Inc.
Via Business Wire
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
From Axonics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.